Vir Biotechnology (VIR) Competitors $5.14 -0.37 (-6.72%) Closing price 04:00 PM EasternExtended Trading$5.12 -0.01 (-0.29%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIR vs. NAMS, HCM, GMTX, IMVT, CPRX, KNSA, TARS, OGN, ALVO, and CNTAShould you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), Gemini Therapeutics (GMTX), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Vir Biotechnology vs. Its Competitors NewAmsterdam Pharma HUTCHMED Gemini Therapeutics Immunovant Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, NAMS or VIR? NewAmsterdam Pharma has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Is NAMS or VIR more profitable? NewAmsterdam Pharma has a net margin of -259.07% compared to Vir Biotechnology's net margin of -2,895.94%. NewAmsterdam Pharma's return on equity of -27.27% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-259.07% -27.27% -25.00% Vir Biotechnology -2,895.94%-50.22%-40.78% Do analysts prefer NAMS or VIR? NewAmsterdam Pharma presently has a consensus price target of $41.55, indicating a potential upside of 61.91%. Vir Biotechnology has a consensus price target of $26.80, indicating a potential upside of 421.40%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has stronger valuation & earnings, NAMS or VIR? NewAmsterdam Pharma has higher earnings, but lower revenue than Vir Biotechnology. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M63.43-$241.60M-$1.62-15.84Vir Biotechnology$74.21M9.62-$521.96M-$4.00-1.29 Do institutionals and insiders have more ownership in NAMS or VIR? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 16.0% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor NAMS or VIR? In the previous week, Vir Biotechnology had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 14 mentions for Vir Biotechnology and 10 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.14 beat Vir Biotechnology's score of 0.77 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNewAmsterdam Pharma beats Vir Biotechnology on 9 of the 14 factors compared between the two stocks. Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIR vs. The Competition Export to ExcelMetricVir BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$765.43M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-1.297.5859.1122.53Price / Sales9.62458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book0.629.9310.916.06Net Income-$521.96M-$53.38M$3.29B$266.28M7 Day Performance1.98%0.05%0.01%-0.76%1 Month Performance0.78%7.08%7.06%3.83%1 Year Performance-32.37%11.92%50.09%24.39% Vir Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRVir Biotechnology3.2145 of 5 stars$5.14-6.7%$26.80+421.4%-29.2%$765.43M$74.21M-1.29580News CoverageAnalyst ForecastInsider TradeNAMSNewAmsterdam Pharma3.8445 of 5 stars$24.05+0.4%$41.55+72.7%+56.4%$2.71B$45.56M0.004News CoverageHCMHUTCHMED2.0509 of 5 stars$15.01+1.2%$28.00+86.5%-12.4%$2.62B$630.20M0.001,811GMTXGemini TherapeuticsN/A$59.650.0%N/A+20.8%$2.58BN/A-59.6530IMVTImmunovant2.9199 of 5 stars$14.69-0.9%$35.20+139.6%-45.2%$2.56BN/A0.00120News CoveragePositive NewsAnalyst ForecastCPRXCatalyst Pharmaceuticals4.9449 of 5 stars$20.59+1.0%$33.20+61.2%+0.3%$2.52B$491.73M12.4880KNSAKiniksa Pharmaceuticals International3.0731 of 5 stars$33.490.0%$41.17+22.9%+36.4%$2.48B$423.24M837.46220News CoverageInsider TradeTARSTarsus Pharmaceuticals1.9951 of 5 stars$58.58+0.7%$66.67+13.8%+120.6%$2.47B$182.95M0.0050News CoveragePositive NewsOGNOrganon & Co.4.8383 of 5 stars$9.40+2.3%$18.00+91.6%-55.6%$2.45B$6.40B2.674,000ALVOAlvotech3.0142 of 5 stars$8.07+0.2%$14.00+73.5%-30.0%$2.43B$491.98M18.341,032Short Interest ↑CNTACentessa Pharmaceuticals3.5162 of 5 stars$16.79+1.4%$31.50+87.6%+17.9%$2.25B$6.85M0.00200News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies NAMS Alternatives HCM Alternatives GMTX Alternatives IMVT Alternatives CPRX Alternatives KNSA Alternatives TARS Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
